IPR decision (Sep 10, 2018):
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent No.
|
Final Written Decision
|
|
IPR2018-01119
|
05/18/2018
|
—
|
Mylan
|
9,833,419
|
Terminated-Settled
|
US 9,833,419 (Noven Pharmaceuticals, Inc.; Exp: 07/10/2028):
1. A monolithic transdermal drug delivery system for estradiol, consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer defining an active surface area and, optionally, (iii) a release liner, wherein the single adhesive polymer matrix layer comprises an adhesive polymer matrix comprising estradiol as the only drug, wherein the adhesive polymer matrix layer has a coat weight of greater than 10 mg/cm.sup.2 and includes greater than 0.156 mg/cm.sup.2 estradiol, and the system achieves an estradiol flux of from 0.0125 to about 0.05 mg/cm.sup.2/day, based on the active surface area.
Leave a Reply